
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
Table of Contents
over 23 years ago
In the Eye of the Stormover 23 years ago
Pharma WANTS YOUover 23 years ago
What They're Not Sayingover 23 years ago
Generic Treatment Claims: Do They Hold Water?over 23 years ago
Generics Battle Heats Upover 23 years ago
HBA's 2003 Woman of the Year





